AdipoGen Life Sciences


CHF 100.00
In stock
AG-CR1-3528-M0055 mgCHF 100.00
AG-CR1-3528-M02525 mgCHF 300.00
More Information
Product Details
Synonyms N-[2-(Cyclohexylamino)-1-(2-methylphenyl)-2-oxoethyl]-N-(3-fluorophenyl)-2-methyl-1H-imidazole-1-acetamide; IDH-C35
Product Type Chemical


MW 462.6
CAS 1355326-35-0
Purity Chemicals ≥98% (NMR)
Appearance White solid.
Solubility Soluble in DMSO (10mg/ml) or ethanol (5mg/ml).
Identity Determined by 1H-NMR.
Smiles O=C(C(C1=C(C)C=CC=C1)N(C2=CC(F)=CC=C2)C(CN3C=CN=C3C)=O)NC4CCCCC4
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent and selective inhibitor of IDH1 (isocitrate dehydrogenase 1) R132H and R132C mutants in vitro with IC50 values of 0.07 and 0.16µM, respectively. Does not inhibit wild-type IDH1 or any of the examined IDH2 isoforms (IC50>100µM). Isocitrate dehydrogenases (IDHs) are nicotinamide adenine dinucleotide (NAD+) and NAD phosphate (NADP+)-dependent enzymes in the tricarboxylic acid (TCA) cycle that catalyze oxidative decarboxylation of isocitrate producing α-ketoglutarate (2-OG) and carbon dioxide. IDH1 and IDH2 are mutated in >70% of lower grade gliomas.
  • Shown to have anti-tumor efficacy in the TS603 glioma cell line and to reduce tumor 2-HG production in HT1080 and U87MG cells.
  • Caused 50-60% growth inhibition over a treatment period of three weeks with no affect in the growth of IDH1 wild-type glioma xenografts in R132H-IDH1 glioma xenografts.
  • Under conditions of near complete 2-HG inhibition, induces demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation.
  • Useful chemical probe to assess the biological consequences of IDH1 mutations and the potential of IDH1 inhibition for treating IDH1 mutant tumors.
  • Requires high doses for in vivo activity, but can be used through oral dosing route.
Product References
  1. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate: L. Dang, et al.; Nature 462, 739 (2009)
  2. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation: P. Koivunen, et al.; Nature 483, 484 (2012)
  3. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype: S. Turcan, et al., Nature 483, 479 (2012)
  4. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism: Z.J. Reitman & H. Yan; J. Natl. Cancer Inst. 102, 932 (2010)
  5. Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo: J. Popovici-Muller, et al.; ACS Med. Chem. Lett. 3, 850 (2012)
  6. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells: D. Rohle, et al.; Science 340, 626 (2013)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.